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INTRODUCTION
Meningiomas are the most common primary tumor of the CNS; there are approximately 28,000 new diagnoses annually in the United States. 1 Currently, there are no approved systemic therapies for meningiomas that recur after local treatment: chemotherapy and hormonal agents have demonstrated minimal benefit in numerous clinical trials. [2] [3] [4] Meningiomas comprise a heterogeneous group of neoplasms driven by mutations in a wide array of tumor suppressor genes and oncogenes. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] Characterization of these mutations has revealed opportunities for rational therapy. [18] [19] [20] For example, a durable therapeutic response has been reported for a metastatic AKT1 E17K-mutant meningioma treated with a pan-AKT inhibitor. 21 Studies also suggest the potential for treating meningioma with immune checkpoint modulators [22] [23] [24] : programmed death ligand 1 (PD-L1) is expressed in a subset of meningiomas, and the tumor microenvironment is immunosuppressive. [22] [23] [24] [25] [26] [27] [28] Higher-grade meningiomas also harbor mutations predicted to generate neoantigens, which may foster susceptibility to immunotherapies. 29 On the basis of these data, we initiated a phase II study of nivolumab, a humanized IgG4 programmed death 1 (PD-1)-blocking monoclonal antibody, in patients with higher-grade meningiomas that recurred after surgery and radiotherapy (ClinicalTrials.gov identifier: NCT02648997). We report here a patient with an atypical meningioma that was not controlled by repeated surgery and radiation but that was highly response to nivolumab.
CASE REPORT
A 50-year-old woman with progressive headaches underwent a gross total resection (surgery 1) of a gadolinium-enhancing right frontal convexity atypical meningioma (WHO grade 2; Fig 1A) . The tumor recurred 10 months later and was treated with stereotactic radiosurgery (SRS; SRS 1, 25 Gy/five fractions). Recurrent atypical meningioma was debulked 17 months (surgery 2) and 21 months (surgery 3) after the original diagnosis. The patient then underwent conventional radiotherapy (RT; conformal RT, 54 Gy/27 fractions). Three months later, she again underwent SRS (SRS 2, 14 Gy/one fraction) because of tumor spread to the sphenoid ridge and infratemporal fossa. Additional debulking surgeries for recurrent atypical meningioma were performed at 46 months (surgery 4) and 49 months (surgery 5). She then received bevacizumab for 11 months, mifepristone for 7 months, and temozolomide for 4 months. Each therapy was discontinued after disease progression occurred. A sixth debulking surgery (surgery 6) at 70 months confirmed recurrent atypical meningioma.
Five weeks later, the patient enrolled in our phase II nivolumab clinical trial. At that time, 75 months after the original diagnosis, painful subcutaneous masses overlaid the right convexity. The patient required oxycodone for scalp pain and dexamethasone (4 mg/day) for worsening headache. Pretreatment magnetic resonance imaging (MRI) showed an enlarging-enhancing right sphenoid wing mass, plaque-like dural enhancement over the right convexity, tumor erosion through the occipital skull, and an Author affiliations and support information (if applicable) appear at the end of this article. I.F.D. and Z.D. contributed equally to this work. S.S. and D.A.R. contributed equally to this work. increased fluid-attenuated inversion recovery (FLAIR) signal abnormality that involved the right hemisphere ( Fig 1B) .
The patient received nivolumab 3 mg/kg on days 1 (dose 1) and 15 (dose 2) of cycle 1 without incident, but her headaches and scalp pain worsened. The scalp masses were notably larger, erythematous, and more tender by day 28. Brain MRI showed significantly enlarged dural-based enhancing lesions, increased T2 and FLAIR signal abnormalities, and enlarged scalp masses ( Fig 1C) . Her physical examination and MRI appeared consistent with progressive disease, and we withheld additional nivolumab. She underwent palliative debulking surgery 3 weeks later (surgery 7). Immediately before surgery, her scalp masses were modestly smaller and less tender. Postoperative MRI showed a subtotal resection ( Fig 1D) .
MATERIALS AND METHODS

Patient Consent
Our patient provided informed consent for our institutional review board-approved study and consented to this publication. We obtained all permissions required by law and by the Dana-Farber Cancer Institute (DFCI)/Harvard Cancer Center to allow the publication of images from the patient.
Immunohistochemistry
We used immunohistochemistry (IHC) to evaluate protein expression using Envision Plus detection (Dako, Carpinteria, CA; Data Supplement) and published protocols. 30, 31 
Multiplexed Immunofluorescence
The protocol for tissue-based multiplexed cyclic immunofluorescence (t-CyCIF) of conventionally prepared formalin-fixed, paraffin-embedded specimens and image analysis are described elsewhere. 32, 33 Antibodies are listed in the Data Supplement.
Oncopanel Sequencing
We used targeted next-generation exome sequencing (Oncopanel version 3; DFCI/Brigham and Women's Hospital [BWH]) to detect mutations and copy number variations in 447 cancer genes. Table 1 and the Data Supplement.
We processed and annotated data as previously described. 9, 34, 35 We calculated tumor mutational burden (TMB) by determining the number of nonsynonymous mutations per megabase (Mb) of exonic sequence data across sequenced genes. 35, 36 
RESULTS
Histopathologic examination of the tissue resected 5 weeks before nivolumab treatment (sample 6) revealed a highly proliferative atypical meningioma (Fig 2A) . In contrast, tissue resected 3 weeks after nivolumab dose 2 (sample 7) had dense fibrosis with extensive immune cell infiltration and necrosis ( Fig 2C) . Tumor cells were absent in the hematoxylin and eosinstained slides, but IHC with a marker of meningioma, SSTR2a 30 (Figs 2B and 2D ), revealed one small cluster (approximately 1,000 cells/µm 2 ) of possible residual tumor cells (which represented < 0.0001% of resected tissue; image and data not shown).
To characterize the effects of nivolumab, we profiled the tumor and its microenvironment using t-CyCIF, a method for highly multiplexed immunofluorescence imaging of formalin-fixed, paraffin-embedded specimens. 32 We imaged 11 markers (Data Supplement) on pre-and post-treatment samples to measure changes in immune cell types and the relative density of the immune infiltrate (Table 1 ; Figs 2E-2H; Appendix Fig A1; Data Supplement) . We have previously shown that PD-L1 is overexpressed in tumor cells of some higher-grade meningiomas, 22 but, in this pretreatment specimen (sample 6), we found PD-L1 restricted to immune cells. Post-treatment (in sample 7), we observed a marked increase in IBA1+/CD14+ macrophages, CD4+ and CD8+ T cells, CD20+ B cells, and FOXP3+ regulatory T cells (T reg cells; Table 1 ; Figs 2E-2H; Appendix Fig A1) . The fraction of CD8+ T cells increased from 7% to 73% (Table  1 ) and CD8+ T-cell density increased from 0.5 to 304 cells/mm 2 ; the CD8+ T cell-to-T reg ratio increased 20-fold (from 5.8 to 115; Figs 2G-2H; Data Supplement). These data are consistent with a highly active antitumor immune response after treatment.
We used targeted-exome sequencing to characterize genomic aberrations in specimens from the original resection (sample 1); the resection before treatment with bevacizumab, mifepristone, and temozolomide (sample 4); and the resection before treatment with nivolumab (sample 6; Fig  1A; Data Supplement). This analysis revealed a significantly elevated TMB of 20.5, 26.6, and 38.0 mutations/Mb in the samples, respectively (Data Supplement). 37 These levels were greater than those of 228 other meningiomas sequenced as part of the BWH/DFCI profile initiative. 35 Copy number variation in the three samples was characteristic of higher-grade aggressive meningioma [38] [39] [40] [41] (Fig 3A; Data Supplement) . Notably, homozygous deletion of exons 2 to 5 of the DNA mismatch repair (MMR) gene MSH2 was present in all three samples (Figs 3A-3B) but was absent in a peripheral-blood specimen.
IHC showed that tumor cells were negative for the MSH2 protein and its heterodimeric partner, MSH6, but that expression of MLH1 and PMS2 protein was retained (Figs 3C-3F). Loss of MSH2/MSH6 in sample 1 demonstrated that MSH2 had been inactivated before any therapy and independent of temozolomide exposure, a known driver of acquired MMR deficiency in gliomas. 42, 43 Thus, the tumor was MMR deficient at the original diagnosis, and there was a progressive increase in TMB (Data Supplement).
The patient resumed nivolumab after surgery 7 and continued biweekly therapy for more than 2 years. MRI scans have shown gradual and continued regression of enhancing lesions and associated T2/FLAIR signal abnormalities ( Fig 1E) . Scalp lesions have disappeared, and narcotics and dexamethasone are no longer required for pain control and cerebral edema.
Given the dramatic response of this MSH2deficient tumor to nivolumab, we investigated the prevalence of elevated TMB and MMR deficiency in meningioma ( Fig 3G; Data Supplement). We used sequencing data from the BWH/ DFCI profile initiative (n = 228 patient cases) 35 or BWH/DFCI patient cases screened only by MMR-protein IHC (n = 237 patient cases) 22, 44 to study specimens from 465 patients (n = 288 with grade 1, n = 132 with grade 2, and n = 45 with grade 3 disease). Among the 228 sequenced specimens, the cohort mean TMB was 4.2 mutations/Mb (grade 1, 4.0; grade 2, 4.4; grade 3, 6.5; Data Supplement). Seven of the 228 specimens had TMBs of 10 or more mutations/Mb, a commonly used threshold for hypermutation 36 ; one of these meningiomas (TMB, 18 mutations/Mb) had a truncating mutation in the DNA MMR regulator SETD2 as well as a splice site mutation in MSH2 of unclear functional significance. We discovered one occurrence with MMR protein loss discovered by IHC (one of 237 occurrences), and sequencing confirmed biallelic inactivation of MSH6 and a TMB of 10 mutations/Mb (Table 2 ; Fig 3G; Data Supplement) . Among the sequenced meningiomas, elevated TMB was significantly positively associated with anaplastic histology, Ki-67 proliferative index, and chromosomal instability 38 but not with prior radiotherapy, radiation induced meningioma, or recurrent tumor (Data Supplement).
In a second cohort of 615 sequenced meningiomas (Foundation Medicine cohort), 14 tumors had a TMB of more than 10 mutations/Mb. Among these 14 specimens, two grade 3 meningiomas had inactivating mutations in MSH2 and MSH6; one grade 2 meningioma had a substitution in the DNA polymerase domain of the POLE subunit of DNA polymerase epsilon, and another grade 3 meningioma had a truncating mutation in SETD2 ( 
DISCUSSION
In our patient with an MSH2-deficient meningioma, nivolumab treatment generated a robust anticancer immune response, as evidenced by dramatically increased infiltrating CD8+ T cells and a durable therapeutic response. Notably, ascopubs.org/journal/po JCO™ Precision Oncology 5 the enlargement of lesions and increased signal abnormalities seen on the MRI after nivolumab reflected pseudoprogression, not tumor growth.
In addition to inactivation of MSH2, sequencing of the patient's tumors revealed missense mutations in POLD1 (R639C), RAD50 (P571L), and POLE (G203E, S30L), but these changes are of unclear significance and are predicted to be nonpathogenic. 45 An increase in TMB from 26.6 mutations/MB in sample 4 (before experimental therapies) to 38.0 in sample 6 raises the possibility that temozolomide can augment TMB in meningioma. However, this neoplasm was MMR deficient at the time of original diagnosis; thus, temozolomide did not drive acquired MMR deficiency.
This work also shows that approximately 2.5% of meningiomas have a high mutation burden, a phenotype that has been linked with neoantigen expression in other tumor types. 46, 47 In a subset of mutation-rich meningiomas, loss of function alterations in MMR and MMR-related genes can be detected. It is possible that other, as yet unknown or undetected, mutations contribute to high TMB in the remaining tumors. In all, this first report, to our knowledge, of a dramatic response of an MMR-deficient meningioma to immunotherapy and our characterization of meningioma cohorts from two different institutions indicate that screening meningiomas is warranted to identify a molecularly defined subtype that is likely responsive to immunotherapy. 
